MicroRNA‑130a‑3p inhibition suppresses cervical cancer cell progression

Oncol Rep. 2023 May;49(5):109. doi: 10.3892/or.2023.8546. Epub 2023 Apr 13.

Abstract

MicroRNAs (miRNAs or miRs) play essential roles in the initiation and progression of human tumors, including cervical cancer. However, the mechanisms underlying their actions in cervical cancer remain unclear. The present study aimed to evaluate the functional role of miR‑130a‑3p in cervical cancer. Cervical cancer cells were transfected with a miRNA inhibitor (anti‑miR‑130a‑3p) and a negative control. Adhesion‑independent cell proliferation, migration and invasion were evaluated. The findings presented herein demonstrated that miR‑130a‑3p was overexpressed in HeLa, SiHa, CaSki, C‑4I and HCB‑514 cervical cancer cells. The inhibition of miR‑130a‑3p significantly reduced the proliferation, migration and invasion of cervical cancer cells. The canonical delta‑like Notch1 ligand (DLL1) was identified as a possible direct target of miR‑103a‑3p. The DLL1 gene was further found to be significantly downregulated in cervical cancer tissues. On the whole, the present study demonstrates that miR‑130a‑3p contributes to the proliferation, migration and invasion of cervical cancer cells. Therefore, miR‑130a‑3p may be used as a biomarker to determine cervical cancer progression.

Keywords: biomarker; cervical cancer; microRNA‑130a‑3p; tumor progression.

MeSH terms

  • Cell Line, Tumor
  • Cell Movement / genetics
  • Cell Proliferation / genetics
  • Female
  • Gene Expression Regulation, Neoplastic
  • HeLa Cells
  • Humans
  • MicroRNAs* / genetics
  • Neoplasm Invasiveness / genetics
  • Uterine Cervical Neoplasms* / genetics
  • Uterine Cervical Neoplasms* / pathology

Substances

  • MicroRNAs

Grants and funding

The present study was funded by FAPESP (grant no. 2016/15831-3), the Research Incentive Program of Barretos Cancer Hospital (PAIP) and PRONON. The present study was also funded by the São Paulo Research Foundation (FAPESP; grant no. 2018/19476-9) and this research was funded by the Brazilian Ministry of Health supported by PRONON/MS (NUP-25000.023997.2018/34) entitled: ‘Identificação de biomarcadores para screening e detecção precoce de tumores no contexto do Sistema Único de Saúde (SUS).’ RMR and MMCM are recipients of a CNPq Productivity fellowship.